Related Experiment Video
Updated: Apr 17, 2026
Isolation and Identification of Waterborne Antibiotic-Resistant Bacteria and Molecular Characterization of their Antibiotic Resistance Genes
Published on: March 3, 2023
Selection and molecular characterization of ceftazidime/avibactam-resistant mutants in Pseudomonas aeruginosa strains
Sushmita D Lahiri1, Grant K Walkup2, James D Whiteaker2
1Infection Innovative Medicines Unit, AstraZeneca R & D Boston, Waltham, MA, USA sushmita.lahiri@astrazeneca.com.
Objectives:
Pseudomonas aeruginosa is an important nosocomial pathogen that can cause a wide range of infections resulting in significant morbidity and mortality. Avibactam, a novel non-β-lactam β-lactamase inhibitor, is being developed in combination with ceftazidime and has the potential to be a valuable addition to the treatment options for the infectious diseases practitioner. We compared the frequency of resistance development to ceftazidime/avibactam in three P. aeruginosa strains that carried derepressed ampC alleles.
Methods:
The strains were incubated in the presence of increasing concentrations of ceftazidime with a fixed concentration (4 mg/L) of avibactam to calculate the frequency of spontaneous resistance. The mutants were characterized by WGS to identify the underlying mechanism of resistance. A representative mutant protein was characterized biochemically.
Results:
The resistance frequency was very low in all strains. The resistant variants isolated exhibited ceftazidime/avibactam MIC values that ranged from 64 to 256 mg/L. All of the mutants exhibited changes in the chromosomal ampC gene, the majority of which were deletions of various sizes in the Ω-loop region of AmpC. The mutant enzyme that carried the smallest Ω-loop deletion, which formed a part of the avibactam-binding pocket, was characterized biochemically and found to be less effectively inhibited by avibactam as well as exhibiting increased hydrolysis of ceftazidime.
Conclusions:
The development of high-level resistance to ceftazidime/avibactam appears to occur at low frequency, but structural modifications in AmpC can occur that impact the ability of avibactam to inhibit the enzyme and thereby protect ceftazidime from hydrolysis.
Insights
Resistance to ceftazidime/avibactam in Pseudomonas aeruginosa develops infrequently. However, mutations in the AmpC enzyme can reduce avibactam efficacy, impacting ceftazidime effectiveness against infections.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Pseudomonas aeruginosa is a significant nosocomial pathogen causing severe infections.
- Ceftazidime/avibactam is a promising new treatment for P. aeruginosa infections.
- Understanding resistance mechanisms is crucial for effective treatment.
Purpose of the Study:
- To determine the frequency of resistance development to ceftazidime/avibactam in P. aeruginosa strains.
- To investigate the genetic and biochemical mechanisms underlying resistance.
Main Methods:
- Spontaneous resistance frequency was determined by incubating strains with increasing ceftazidime/avibactam concentrations.
- Whole Genome Sequencing (WGS) identified resistance mechanisms in mutants.
- Biochemical characterization of mutant AmpC enzymes was performed.
Main Results:
- Resistance to ceftazidime/avibactam developed at a very low frequency across all tested strains.
- Resistant mutants showed alterations in the chromosomal ampC gene, primarily deletions in the Ω-loop region.
- A characterized mutant AmpC enzyme demonstrated reduced avibactam inhibition and increased ceftazidime hydrolysis.
Conclusions:
- High-level resistance to ceftazidime/avibactam emerges infrequently in P. aeruginosa.
- Structural changes in AmpC can compromise avibactam's inhibitory activity and ceftazidime's stability.
More Related Videos
Related Concept Videos
01:25Mechanism of Antibiotic Resistance in MRSA
01:25Clinical Significance of Antibiotic Resistance
01:30Development of Antibiotic Resistance
00:57Antibiotic Selection
01:28Gene Regulation in Microbial Communities: Quorum Sensing